Scalzo Richard William sold $20K of CBIO
Scalzo Richard William (Chief Financial Officer) sold 1,112 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.99 on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides incremental information about insider activity but does not introduce new operational or financial fundamentals for Crescent Biopharma.
Market read
Traders may treat this as low-signal sentiment/flow data rather than a standalone catalyst.
What to watch
The disclosed sale size is small (~$20k) and explicitly pre-arranged, which often limits interpretability versus unscheduled sales.
Background
SEC Form 4 insider transaction: CFO Richard William Scalzo sold shares in an open-market transaction under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Crescent Biopharma CFO Richard William Scalzo sold 1,112 shares at $17.99 under a pre-arranged 10b5-1 plan, per Form 4.
Likely limited near-term price impact; any effect is more sentiment/flow-related than fundamental.
The filing is a pre-arranged 10b5-1 open-market sale with modest disclosed value (~$20k) and no accompanying company-specific news (guidance, trials, deals, or enforcement).
Market effects
No clear sector read-through; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with private views on liquidity or risk, so traders may still watch for follow-on selling or other insider actions.
Key entities
- issuerCrescent Biopharma, Inc.
Company whose CFO filed the Form 4 insider sale disclosure.
- insiderRichard William Scalzo
CFO who sold 1,112 shares at $17.9900 on 2026-06-22 under a 10b5-1 plan.
